Fuji Pharma Co., Ltd.
10.50
EUR
0.00
(0.00%)
ISIN
JP3816200004
Return %
Stock
S&P 500
1Y
16.02
14.20
3Y
44.83
81.12
5Y
23.53
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Shuhei Morita
- Full Time Employees
- 1,760
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 5-7 Sanban-cho Tokyo TY Japan 102-0075
- IPO Date
- Jun 22, 1995
- Website
- fujipharma.jp
- Similar Companies
- Business
- Fuji Pharma Co., Ltd. engages in the research, development, manufacture, and marketing of pharmaceutical products primarily in Japan with international operations. The company's core product offerings include injection agents, internal drugs, drugs for external use, and diagnostic products. Fuji Pharma specializes notably in hormone medicines for obstetrics and gynecology, injectable drugs for radiological use such as radiopaque dyes for urinary tracts and blood vessels, and generic drugs in the women's healthcare area. It also produces pharmaceutical excipients including unique formulations like Fujicalin, F-Melt, and FujiSil. Founded in 1965, the company is headquartered in Chiyoda-ku, Tokyo, Japan. In recent developments, Fuji Pharma has been advancing its mid-term business plan focusing on three growth strategies: Women’s Healthcare, Biosimilars, and Global Contract Manufacturing Organization (CMO) services. The company has expanded strategic partnerships, including a notable collaboration with Alvotech to co-develop and commercialize biosimilar products, now covering six biosimilar candidates. Fuji Pharma also continues to enhance production capabilities with new manufacturing lines for high-potency injectable syringes and has aligned its sustainability initiatives with the Science Based Targets initiative (SBTi) to reduce greenhouse gas emissions. These efforts reflect a significant strategic shift aiming at expanding global biosimilars and contract manufacturing business segments while reinforcing its foothold in women’s health pharmaceuticals. Fuji Pharma operates within the pharmaceutical industry focusing on healthcare, biosimilars, and medical product manufacturing segments. The company serves healthcare providers, hospitals, and pharmaceutical distributors both domestically and internationally. Fuji Pharma leverages its extensive product portfolio and technological innovation to address demands in obstetrics, gynecology, radiology, and general medicine sectors. It maintains a parent-company relationship with Fuji Pharmaceutical Holdings. The combination of legacy pharmaceutical products and cutting-edge biosimilars underpins Fuji Pharma’s comprehensive market approach for growth and sustained competitiveness.